LSPN Connect: micro-managing with Pendulum Therapeutics
06-08-2020
KIPA hires former Decode Genetics director
06-08-2020
LSPN Connect: When IP and COVID-19 meet
10-07-2020
Vchal / Shutterstock.com
The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
LSPN Connect, Kelly Morgan, Arbor Biotechnologies, CRISPR, Broad Institute, diversity, in-house counsel, biotech, genetics
